Longitudinal Visual Biomarkers in Dominant Optic Atrophy: A Systematic Review and Meta-Analysis.
Аннотация
BACKGROUND
Dominant Optic Atrophy (DOA) causes slowly progressive visual decline usually beginning in childhood. As new therapies come to clinical trial, the choice of biomarkers to be used as clinical trial endpoints has become a critical question to be addressed.
METHODS
We undertook a systematic review and meta-analysis of studies reporting longitudinal data of any biomarker in DOA patients.
RESULTS
In total, seven studies were included in the systematic review, and four presented paired results compatible with meta-analysis. Visual acuity was the only biomarker found with reported longitudinal data. Of the included studies in the meta-analysis, the rate of yearly visual acuity decline (0.022 LogMAR/year., 95% CI: -0.008 to 0.052) was not significantly different from zero (Z = 1.4, p = 0.155).
CONCLUSION
Quantifying this slow rate of visual decline has implications for future study design and suggests that further natural history studies examining alternative biomarkers in DOA are warranted.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.